CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of April 18, 2024, CRIS stock price declined to $15.22 with 19,173 million shares trading.

CRIS has a beta of 2.89, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.10 to the broad based SPY ETF.

CRIS has a market cap of $89.71 million. This is considered a Micro Cap stock.

Last quarter Curis reported $3 million in Revenue and -$2.03 earnings per share. This fell short of revenue expectation by $-324,000 and exceeded earnings estimates by $.08.

In the last 3 years, CRIS stock traded as high as $348.00 and as low as $3.80.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VTI, VXF, DFUS, DFAC, AVSC.

CRIS stock has underperformed the market in the last year with a return of -23.1%, while SPY returned +22.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CRIS shares. However, CRIS has outperformed the market in the last 3 month and 2 week periods, returning +19.1% and +13.6%, while SPY returned +6.1% and -3.8%, respectively. This indicates CRIS has been having a stronger performance recently.

CRIS support price is $14.83 and resistance is $17.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS stock will trade within this expected range on the day.